374 related articles for article (PubMed ID: 15150181)
1. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
Goldstein EJ; Snydman DR
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii29-36. PubMed ID: 15150181
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.
Nix DE; Majumdar AK; DiNubile MJ
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii23-8. PubMed ID: 15150180
[TBL] [Abstract][Full Text] [Related]
4. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Goldstein EJ
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S106-11. PubMed ID: 12173118
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis: ertapenem for complicated intra-abdominal infections.
Falagas ME; Peppas G; Makris GC; Karageorgopoulos DE; Matthaiou DK
Aliment Pharmacol Ther; 2008 May; 27(10):919-31. PubMed ID: 18266994
[TBL] [Abstract][Full Text] [Related]
6. Bacteriology and antibiotic susceptibility of community-acquired intra-abdominal infection in children.
Lin WJ; Lo WT; Chu CC; Chu ML; Wang CC
J Microbiol Immunol Infect; 2006 Jun; 39(3):249-54. PubMed ID: 16783457
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.
Vestweber KH; Grundel E
Eur J Surg Suppl; 1994; (573):57-60. PubMed ID: 7524797
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of ertapenem.
Teppler H; Gesser RM; Friedland IR; Woods GL; Meibohm A; Herman G; Mistry G; Isaacs R
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii75-81. PubMed ID: 15150186
[TBL] [Abstract][Full Text] [Related]
9. Activity of a novel carbapenem, doripenem, against anaerobic pathogens.
Goldstein EJ; Citron DM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):447-54. PubMed ID: 19249176
[TBL] [Abstract][Full Text] [Related]
10. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy.
Tice AD
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii83-6. PubMed ID: 15150187
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Gesser RM; McCarroll K; Teppler H; Woods GL
J Antimicrob Chemother; 2003 May; 51(5):1253-60. PubMed ID: 12697633
[TBL] [Abstract][Full Text] [Related]
12. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
Hammond ML
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii7-9. PubMed ID: 15150178
[TBL] [Abstract][Full Text] [Related]
13. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
[TBL] [Abstract][Full Text] [Related]
15. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
Solomkin JS; Yellin AE; Rotstein OD; Christou NV; Dellinger EP; Tellado JM; Malafaia O; Fernandez A; Choe KA; Carides A; Satishchandran V; Teppler H;
Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
[TBL] [Abstract][Full Text] [Related]
16. Ertapenem.
Parakh A; Krishnamurthy S; Bhattacharya M
Kathmandu Univ Med J (KUMJ); 2009; 7(28):454-60. PubMed ID: 20502094
[TBL] [Abstract][Full Text] [Related]
17. Ertapenem: a review of its use in the management of bacterial infections.
Curran M; Simpson D; Perry C
Drugs; 2003; 63(17):1855-78. PubMed ID: 12921489
[TBL] [Abstract][Full Text] [Related]
18. Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy.
DiNubile MJ; Friedland IR; Chan CY; Motyl MR; Giezek H; McCarroll K; Shivaprakash M; Quinn JP; Weinstein RA; Chow JW
Diagn Microbiol Infect Dis; 2007 Aug; 58(4):491-4. PubMed ID: 17509789
[TBL] [Abstract][Full Text] [Related]
19. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell KL; Gesser RM
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S119-25. PubMed ID: 12173120
[TBL] [Abstract][Full Text] [Related]
20. Properties and potential of ertapenem.
Livermore DM; Sefton AM; Scott GM
J Antimicrob Chemother; 2003 Sep; 52(3):331-44. PubMed ID: 12917243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
